A Phase 1b/2, Dose-Escalation Study of Elotuzumab (Humanized Anti-CS1 Monoclonal IgG1 Antibody) in Relapsed Multiple Myeloma

Clinical trial NCT00742560 · COMPLETED

Trial details

NCT number: NCT00742560
Sponsor: AbbVie (prior sponsor, Abbott)
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Hematologic Cancer

Start date: 2008-08-01
Primary completion: 2016-10-01
Enrollment: 101

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.